Lowest Price Guaranteed
Pages
132
Last Updated
June 2026
View Count
18703
The global squamous non-small cell lung cancer market, valued at USD 9.3 billion in 2025, is projected to reach USD 10.0 billion in 2026 and USD 18.3 billion by 2035, representing a CAGR of 7.9% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Non-small cell lung cancer (NSCLC) represents the most common form of lung cancer, accounting for approximately 85% of all lung cancer cases worldwide. This broad category encompasses several histologic subtypes, with adenocarcinoma being the most prevalent, followed by squamous cell carcinoma. In NSCLC, cancer cells grow and spread more slowly than small cell lung cancer, providing a longer window for NSCLC treatment intervention.
Squamous NSCLC originates from squamous cells lining the lung airways and typically arises centrally in the larger bronchi, distinguishing it from adenocarcinoma, which tends to occur in the peripheral lung regions. This subtype is more strongly associated with tobacco smoking than other forms of NSCLC. Further, the incidence of squamous cell lung cancer has shown clear regional variations, with the highest age-standardized incidence rates occurring in central and eastern Europe and eastern Asia.
Drug developers are increasingly focusing on squamous NSCLC due to significant unmet medical needs and the limited treatment options specific to this subtype. Unlike adenocarcinoma, which has well-defined actionable mutations like EGFR, ALK, and ROS1, squamous NSCLC harbors fewer targetable driver mutations, making it resistant to traditional targeted therapies. Further, squamous NSCLC is increasingly being viewed as a separate commercial opportunity rather than a subset of NSCLC. Multiple late-stage trials are now targeting squamous NSCLC patients instead of the broader NSCLC population. Notably, BioNTech’s Phase III gotistobart study resumed recruitment exclusively for squamous NSCLC after data indicated divergent outcomes between squamous and non-squamous groups.
In the absence of suitable targeted therapies, immunotherapy with or without chemotherapy has become the cornerstone of squamous NSCLC treatment. However, survival-related outcomes remain poorer for patients with squamous NSCLC than in those with non-squamous NSCLC. This therapeutic gap has created a compelling opportunity for pharmaceutical innovation and prompted drug developers to work on advanced cancer therapeutics.
| Drug | Developer | Year of Establishment | Headquarters (Region) | Phase of Development | Mechanism of Action |
| Necitumumab | Eli Lilly | 1876 | Indianapolis, US | Approved | EGFR Inhibitor |
| Pembrolizumab | Merck | 1891 | New Jersey, US | Approved | PD-1 Inhibitor |
| Nivolumab | Bristol-Myers Squibb | 1887 | New York, US | Approved | PD-1 Inhibitor |
| Cemiplimab | Regeneron Pharmaceuticals | 1988 | New York, US | Approved | PD-1 Inhibitor |
| Ipilimumab | Bristol-Myers Squibb | 1887 | New York, US | Approved | CTLA-4 Inhibitor |
Based on the research, we have segmented the Squamous Non-Small Cell Lung Cancer Market into therapeutic type, drug class, treatment line, end-user, and geographical regions.
By Therapeutic Type
By Drug Class
By Treatment Line
By End-User
By Geographical Regions
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:
This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various therapeutic types, such as immunotherapies, combination therapies, chemotherapy, targeted therapies and radiation therapies.
Currently, the immunotherapies subsegment captures the majority (more than 35%) of the market share. This is due to their ability to significantly improve survival outcomes and provide durable responses compared to traditional chemotherapy. The introduction of immune checkpoint inhibitors targeting the PD-1, PD-L1, and CTLA-4 pathways and immunocytokines has transformed the treatment landscape for squamous NSCLC, particularly in advanced and metastatic settings where targeted therapy options are relatively limited.
Further, the market for immunotherapies is expected to grow at a faster pace as these therapies have become a standard of care across multiple lines of treatment, either as monotherapy or in combination with chemotherapy. This can be attributed to their demonstrated efficacy, favorable benefit-risk profile, and broad applicability across patient populations. Moreover, strong clinical evidence and an increasing number of regulatory approvals for immunotherapy-based regimens have contributed to the segment's dominant market position.
This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various drug classes, such as PD-1 / PD-L1 inhibitors, platinum-based drugs, EGFR inhibitors, VEGF inhibitors and ALK inhibitors.
Currently, the PD-1 / PD-L1 inhibitor subsegment captures the majority of the market share. This is because they have become a cornerstone of treatment across multiple disease stages and lines of therapy. Further, these immunotherapies work by restoring the immune system's ability to recognize and attack tumor cells, resulting in improved overall survival rates and better clinical outcomes when compared to conventional chemotherapy. Further, their broad applicability in patients with advanced squamous NSCLC has led to its widespread adoption in clinical practice.
Notably, the PD-1 / PD-L1 inhibitor segment is expected to grow at a significant pace during the forecast period due to the continued expansion of immunotherapy indications and increasing utilization across earlier stages of squamous NSCLC. Further, ongoing clinical trials are evaluating novel combination strategies involving PD-1 / PD-L1 inhibitors with chemotherapy, targeted therapies, and other immunotherapeutic agents. This is expected to further improve treatment outcomes and expand eligible patient populations.
This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various treatment lines, such as first-line treatment, second-line treatment, adjuvant therapies, third-line and beyond therapies, and neoadjuvant therapies.
Currently, the first-line treatment segment occupies the highest market share (close to 60%). This can be attributed to the fact that it represents the initial and most widely utilized treatment setting for the majority of newly diagnosed patients with advanced diseases. Further, these regimens have demonstrated meaningful improvements in overall survival, progression-free survival, and response rates when compared with historical chemotherapy-only approaches. Further, it is important to note that nearly all eligible patients receive first-line systemic therapy, while only a small number of patients proceed to later treatment lines due to disease progression, clinical status, or mortality. This results in increased patient volume and treatment duration in the first-line treatment setting, resulting in the highest market value contribution.
The market for neoadjuvant therapies is expected to grow at a significant pace during the forecast period owing to the expanding use of preoperative systemic treatment in resectable and potentially resectable squamous NSCLC. Additionally, clinical studies have shown that neoadjuvant immunotherapy-based regimens can increase pathologic response rates, reduce residual tumour burden, and improve event-free survival before surgery. As regulatory approvals and treatment guidelines increasingly incorporate neoadjuvant immunotherapy approaches, more patients are becoming eligible for therapy earlier in the disease course, consequently contributing towards a higher growth rate.
This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various end-users, such as hospitals, specialty clinics and other end-users.
Hospitals hold the largest share of the squamous NSCLC market because they serve as the primary centers for diagnosis, staging, treatment initiation, and long-term management of lung cancer patients. The treatment of squamous NSCLC often requires a multidisciplinary approach involving oncologists, pulmonologists, thoracic surgeons, radiologists, pathologists, and specialized nursing teams, all of which are typically available within hospital settings. In addition, hospitals are the main providers of complex and high-cost therapies, including immunotherapies, chemotherapy, combination regimens, surgery, and radiation therapy.
The specialty clinics segment is expected to grow at a significant pace during the forecast period, owing to the increasing shift toward outpatient cancer care and the growing demand for specialized oncology services. Notably, these clinics offer focused expertise in cancer management and convenient access to advanced therapies, including immunotherapies and targeted treatments. Further, improvements in treatment administration and monitoring have enabled many therapies to be delivered safely in outpatient settings, thereby reducing the need for prolonged hospital visits.
According to our projections, North America is likely to capture the majority of the market share in the current year. This can be attributed to its advanced healthcare infrastructure, high adoption of innovative oncology therapies, and strong presence of leading pharmaceutical and biotechnology companies. In addition, favorable reimbursement frameworks and strong clinical research activity have accelerated the uptake of newly approved therapies within this region.
The market in Asia-Pacific is likely to grow at the highest CAGR during the forecast period. This is due to the rising incidence of lung cancer, expanding healthcare access, and increasing investments in cancer care infrastructure across countries such as China, India, Japan, and South Korea. Further, continued exposure to high-risk factors such as smoking and air pollution is rapidly contributing to a growing patient pool in the region.
| Key Report Attribute | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 10.0 Billion | |
| Market Size 2035 | $ 18.3 Billion | |
| CAGR (Till 2035) | 7.9% | |
| Segments Covered |
|
|
| Key Squamous Non-Small Cell Lung Cancer Drugs Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |